Connect Biopharma Presents Abstract About Results From Rademikibart Global Phase 2b Trial In Patients With Moderate-to-severe Asthma At ATS 2024 international Conference
$CNTB
Biotechnology: Pharmaceutical Preparations
Health Care
- Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24
- Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24
- End of Phase 2 (EoP2) meeting is scheduled with the U.S. Food and Drug Administration (FDA) for Q2 2024